Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

FDA Concerns At Catalent Site Spurred Novo Nordisk's Wegovy Supply Woes: Report

Last week, Catalent Inc (NYSE:CTLT) received an FDA write-up for its syringe filling facility in Belgium, "allegedly" the culprit behind supply shortage for Novo Nordisk A/S's (NYSE:NVO) obesity drug Wegovy, reported BioProcess International reported.

  • An FDA inspection of the CDMO's filling site in Brussels yielded a Form 483, the publication said, calling it a "recent" inspection.
  • "We are treating the FDA's 483 observations at the Brussels, Belgium, site very seriously and are working closely with them to resolve these, and with customers to minimize any potential disruptions this may cause to their supply chains," a Catalent spokesperson told BioProcess Insider.
  • Related: Novo Nordisk Shares Slump As Wegovy Hits US Supply Issues; Deutsche Bank Downgrades.
  • While the publication reports that Catalent could not confirm Novo Nordisk is a customer at the Brussels site, the BioProcess report referenced a note from Jefferies analyst David Windley naming the Brussels site as the primary fill-finish supplier for Novo's Wegovy. 
  • In the note, Windley blamed the 483 for Wegovy's recent supply hurdles. He also noted that the site had been handed 12 483s in nine FDA visits.
  • Catalent says its Brussels facility stands at 265,287 square feet on its website. It boasts one of the largest syringe-filling capacities in Europe at over 175 million units per year, the CDMO says.
  • Novo Nordisk's shortage news came just a few days after it announced an investment of DKK 17 billion to expand its manufacturing hub in Kalundborg, Denmark, with three new facilities.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.